|
|
Volumn 12, Issue 11, 2013, Pages 823-824
|
|
Advances in prostate cancer treatment
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABIRATERONE ACETATE;
AFLIBERCEPT;
ANDROGEN RECEPTOR;
ANTINEOPLASTIC AGENT;
ARN 509;
BICALUTAMIDE;
CABAZITAXEL;
CABOZANTINIB;
DASATINIB;
DENDRITIC CELL VACCINE;
DENOSUMAB;
DOCETAXEL;
ENZALUTAMIDE;
FLUTAMIDE;
GONADORELIN;
HISTONE DEACETYLASE INHIBITOR;
IPILIMUMAB;
OGX 11;
ONCOLYTIC VIRUS;
ORTERONEL;
PADELIPORFIN;
PLACEBO;
PROSTATAK;
PROTEIN KINASE INHIBITOR;
RADIUM CHLORIDE RA 223;
RILIMOGENE GALVACIREPVEC;
SIPULEUCEL T;
TASQUINIMOD;
TESTOSTERONE;
THYMIDINE KINASE PLUS VALACICLOVIR;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
VIRUS VECTOR;
ABLATION THERAPY;
AMINO ACID SUBSTITUTION;
BINDING AFFINITY;
BONE METASTASIS;
CANCER IMMUNIZATION;
CANCER PROGNOSIS;
CANCER RADIOTHERAPY;
CANCER RESISTANCE;
CANCER STAGING;
CANCER SURGERY;
CANCER THERAPY;
CASTRATION;
CASTRATION RESISTANT PROSTATE CANCER;
CELL THERAPY;
COMPETITIVE INHIBITION;
DRUG APPROVAL;
DRUG COST;
DRUG EFFICACY;
DRUG INDICATION;
DRUG MARKETING;
DRUG PROTEIN BINDING;
DRUG SPECIFICITY;
DRUG TARGETING;
GENE MUTATION;
HUMAN;
METASTASIS;
NOTE;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
PROSTATE CANCER;
PROSTATECTOMY;
SURVIVAL TIME;
TESTOSTERONE BLOOD LEVEL;
TUMOR MICROENVIRONMENT;
CANCER VACCINES;
DRUGS, INVESTIGATIONAL;
HUMANS;
MALE;
PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;
|
|
EID: 84887079686
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd4068 Document Type: Note |
|
Times cited : (64)
|
|
References (3)
|
